NCT03005353

Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Suppositories.

Completed Phase 2, PHASE3 Last updated 9 June 2020

What this trial tests

Phase 2, PHASE3 trial testing Cumin seed extract in Infection, Fungal in 100 participants. Completed in 31 January 2020.

Timeline

1 March 2018

Primary endpoint
31 October 2019

31 January 2020

Quick facts

Lead sponsor	Assiut University
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	100
Start date	1 March 2018
Primary completion	31 October 2019
Estimated completion	31 January 2020
Sites	1 location across Egypt

Drugs / interventions tested

• Cumin seed extract — full drug profile →
• clotrimazole (clotrimazole) — full drug profile →

Conditions studied

• Infection, Fungal — all drugs for Infection, Fungal →

Sponsor

Assiut University

Who can join

Adults 18 to 49, female only, with Infection, Fungal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fungal infections have increased over the last two decades, largely because of the increasing size of the population at risk, including patients who are immunocompromised, broad-spectrum antibiotics and intravascular catheter users. Essential oils and other extracts of plants have evoked interest as sources of natural products. They have been shown to possess antibacterial, antifungal, antiviral, insecticidal and antioxidant properties. To the best of our knowledge, no study has examined the efficacy of cumin seed extract on relieving vulvovaginal candidiasis in vivo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.